Engineering of an Exosome-Based GPIHBP1 mRNA Delivery System for Efficient Therapy of Familial Hypertriglyceridemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01828 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Ying Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong 271000, China. Hauptthemen laut MEDLINE: Exosomes, RNA, Messenger, Receptors, Lipoprotein, Hyperlipoproteinemia Type I. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Science, Technology and Innovation Commission of Shenzhen Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Familial hypertriglyceridemia (FHTG), a severe subtype of primary hypertriglyceridemia caused by mutations in GPIHBP1 and other related genes, is linked to life-threatening cardiovascular complications. Current therapies inadequately address the underlying genetic pathology. Here, we developed a novel exosome-based mRNA delivery platform to restore functional glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) expression, providing a targeted therapeutic strategy for FHTG. Using GPIHBP1-/- mice as disease models, we engineered exosomes (ExoGPIHBP1) encapsulating GPIHBP1 mRNA via an optimized vector. These exosomes exhibited high biostability and preferential liver accumulation after systemic administration, enabling efficient protein translation. Consequently, treatment significantly reduced serum triglyceride (TG) levels, attenuated lipid accumulation, and ameliorated liver steatosis. Our study explores exosome-mediated GPIHBP1 mRNA therapy as a precise, safe, and effective strategy for FHTG, highlighting a considerable translational potential for genetic dyslipidemias. The platform advances RNA-based therapeutics by bridging the gap between gene therapy and clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong 271000, China.
- Clinical and Basic Medical Sciences at Shandong First Medical University & Shandong Academy of Medical Science, Jinan, Shandong 250117, China.
- Shanghai Key Laboratory of Hydrogen Science & Center of Hydrogen Science, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
- Shenzhen Research Institute, Shanghai Jiao Tong University, Shenzhen 518057, China.
ORCID-Profile: Chao Xia, Qianjun He, Guohua Song
Förderung
- Science, Technology and Innovation Commission of Shenzhen Municipality
- National Natural Science Foundation of China
Zitieren
APA
Cao, Y., Meng, X., Xu, X., Xia, C., Yang, C., Cui, X., He, Q., & Song, G. (2025). Engineering of an Exosome-Based GPIHBP1 mRNA Delivery System for Efficient Therapy of Familial Hypertriglyceridemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01828
Vancouver
Cao Y, Meng X, Xu X, Xia C, Yang C, Cui X, et al. Engineering of an Exosome-Based GPIHBP1 mRNA Delivery System for Efficient Therapy of Familial Hypertriglyceridemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01828
BibTeX
@article{Cao2025,
author = {Cao, Ying and Meng, Xiao and Xu, Xinxin and Xia, Chao and Yang, Chao and Cui, Xinyu and He, Qianjun and Song, Guohua},
title = {Engineering of an Exosome-Based GPIHBP1 mRNA Delivery System for Efficient Therapy of Familial Hypertriglyceridemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01828}
}
EUVIMED